Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety Profile of Cisatracurium Besylate for Intra-abdominal Hypertension
NCT05172531Unknown
- Sponsor
- Tianjin Nankai Hospital
- Start
- Aug 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of cisatracurium in Intra-abdominal hypertension (IAH) and abdominal compartment syndrome (ACS) (2 arms), sponsored by Tianjin Nankai Hospital. Primary endpoint: All-cause 28-day mortality. Status: unknown.
02
Drugs
cisatracurium
03
Conditions
Intra-abdominal hypertension (IAH)abdominal compartment syndrome (ACS)
Beyond the preview
Go deeper on NCT05172531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05172531.